Anacor has created a highly focused and productive research organization that has progressed several internal compounds into the clinic since our founding in 2002. With additional compounds at various early stages, preclinical and Phase I, Anacor has a growing pipeline, with an expanding clinical development portfolio focused on developing topical applications of our compounds to treat fungal, bacterial and inflammatory diseases.